Group Tschan

Group Tschan

Funding

Group Tschan

SNSF; M. Tschan; PI; 2017-2021; Identification and analysis of PU.1 cell death pthways to improve leukemia therapy

SNSF; M. Tschan; Co-PI; 2016-2019; Analyzing and modulating the epigenetic landscape of CDX2 as well as studying its function in colorectal cancer pathology

Cancer Research Switzerland; M. Tschan; Co-PI; 2016-2018; Interaction of Her2 and Molecular Chaperones in Gastroesophageal Adenocarcinomas - Biologic Significance and Therapeutic Impact

Swiss Cancer Research Foundation; M. Tschan; PI; 2014-2019; DAPK2 - a versatile kinase at the crossroad of differentiation, apoptosis and autophagy in AML?

Swiss Cancer Research Foundation; M. Tschan; Co-PI; 2014-2017; Autophagy modulation in the treatment of pNETs

UniBE international 2021; M. Tschan; PI: 2017-2021; Modulating autophagy to improve targeted breast cancer therapy

UniBE Initiator Grants; M. Humbert; PI: 2017-2018; Understanding the role of Macro- and Chaperone-Mediated Autophagy (CMA) in Leukemia Development and Sustainment

National MD-PhD program (SAMW); K. Seiler; Scholarship recipient; Glycolytic metabolism and autophagy in AML - considerations for AML biology and
therapy

COST Action CA15138; Co-PI; 2016-2020; "European Network of Multidisciplinary Research and Translation of Autophagy Knowledge" (TRANSAUTOPHAGY)